Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:34 PM
Ignite Modification Date: 2025-12-24 @ 10:34 PM
NCT ID: NCT05112835
Eligibility Criteria: Inclusion Criteria: 1. Diagnosis of nAMD 2. ≥50 years of age at index date 3. Receipt of at least one injection of brolucizumab during the eligibility period 4. Able and willing to provide signed informed consent Exclusion Criteria: 1. Received treatment for retinal vein occlusion, diabetic macular edema (DME) and/or myopic choroidal neovascularization (mCNV), and/or has received a new diagnosis of diabetes-related macular degeneration in the index eye within 6 months prior to the index date 2. Receipt of anti-VEGF treatment other than brolucizumab in the index eye at index date 3. Any active intraocular or periocular infection or active intraocular inflammation in the index eye at index date 4. Has been on anti-VEGF treatment for longer than 3 years (before index date) 5. Has a contraindication and is not eligible for treatment with brolucizumab according to the Beovu® (brolucizumab) Summary of Product Characteristics (SmPC) ("Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)" 2020) 6. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from participating in the study 7. Participating in a parallel interventional clinical study 8. Participating in a parallel non-interventional study (NIS) generating primary data for an anti- VEGF drug.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 50 Years
Study: NCT05112835
Study Brief:
Protocol Section: NCT05112835